Filtered By:
Drug: Temodar
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 1478 results found since Jan 2013.
Temozolomide sensitizes ARID1A-mutated cancers to PARP inhibitors
We report here that mammalian cells with ARID1A deficiency harbor accumulated DNA base lesions and increased abasic (AP) sites, products of glycosylase in the first step of base excision repair (BER). ARID1A mutations also delayed recruitment kinetics of BER long-patch repair effectors. Although ARID1A-deficient tumors were not sensitive to monotherapy with DNA-methylating temozolomide (TMZ), the combination of TMZ with PARP inhibitors (PARPi) potently elicited double strand DNA breaks, replication stress, and replication fork instability in ARID1A-deficient cells. The TMZ and PARPi combination also significantly delayed i...
Source: Cell Research - June 12, 2023 Category: Cytology Authors: Zheng-Cheng Yu Tianhe Li Ellen Tully Peng Huang Chih-Ning Chen Philipp Oberdoerffer Stephanie Gaillard Ie-Ming Shih Tian-Li Wang Source Type: research
Radiation Therapies in Cancer
Cancer Treat Res. 2023;185:59-77. doi: 10.1007/978-3-031-27156-4_4.ABSTRACTA crucial element of cancer treatment is radiation therapy that is used to destroy tumors and cancer cells through radiation. Another essential component is immunotherapy that helps immune system to combat cancer. The combination of both radiation therapy and immunotherapy is being focused recently for the treatment of many tumors. Chemotherapy includes the use of some chemical agent to control the growth of cancer, whereas irradiation involves the use of radiations of high energy to kill cancer cells. The union of both became the strongest practice...
Source: Cancer Control - June 12, 2023 Category: Cancer & Oncology Authors: Muhammad Rizwan Tariq Shinawar Waseem Ali Noor Fatima Aqsa Jabeen Asma Saleem Qazi Amna Hameed Waseem Safdar Source Type: research
Toward a theranostic device for gliomas
CONCLUSIONS: We present an improved formulation of PVA-MBs to achieve a multifunctional device with adhesion ability, cytotoxicity on glioblastoma cells and supporting imaging.PMID:37300942 | DOI:10.1016/j.bbrc.2023.05.089
Source: Biochemical and Biophysical Research communications - June 10, 2023 Category: Biochemistry Authors: Gaio Paradossi Rachel Grossman Francesco Riccitelli Federica Todaro Zvi Ram Sara Schioppa Fabio Domenici Source Type: research
Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation
In this study, Res was found to effectively improve chemosensitivities of different GBM cells to TMZ, which was evaluated by CCK-8, flow cytometry, and cell migration assay. The combined use of Res and TMZ downregulated STAT3 activity and STAT3-regulated gene products, thus inhibited cell proliferation and migration, as well as induced apoptosis, accompanied by increased levels of its negative regulators: PIAS3, SHP1, SHP2, and SOCS3. More importantly, a combination therapy of Res and TMZ reversed TMZ resistance of LN428 cells, which could be related to decreased MGMT and STAT3 levels. Furthermore, the JAK2-specific inhibi...
Source: Cell Research - June 10, 2023 Category: Cytology Authors: Moli Wu Danyang Song Hui Li Nisar Ahmad Hong Xu Xiaobo Yang Qian Wang Xiaoxin Cheng Sa Deng Xiaohong Shu Source Type: research
Toward a theranostic device for gliomas
CONCLUSIONS: We present an improved formulation of PVA-MBs to achieve a multifunctional device with adhesion ability, cytotoxicity on glioblastoma cells and supporting imaging.PMID:37300942 | DOI:10.1016/j.bbrc.2023.05.089
Source: Biochemical and Biophysical Research communications - June 10, 2023 Category: Biochemistry Authors: Gaio Paradossi Rachel Grossman Francesco Riccitelli Federica Todaro Zvi Ram Sara Schioppa Fabio Domenici Source Type: research
Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition
Biochim Biophys Acta Mol Basis Dis. 2023 Jun 5:166782. doi: 10.1016/j.bbadis.2023.166782. Online ahead of print.ABSTRACTTemozolomide (TMZ) is the leading chemotherapeutic agent used for glioma therapy due to its good oral absorption and blood-brain barrier permeability. However, its anti-glioma efficacy may be limited due to its adverse effects and resistance development. O6-Methylguanine-DNA-methyltransferase (MGMT), an enzyme associated with TMZ resistance, is activated via the NF-κB pathway, which is found to be upregulated in glioma. TMZ also upregulates NF-κB signaling like many other alkylating agents. Magnolol (MG...
Source: Biochimica et Biophysica Acta - June 7, 2023 Category: Biochemistry Authors: Moumita Kundu Subhayan Das Suvendu Nandi Dibakar Dhara Mahitosh Mandal Source Type: research
Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)
CONCLUSIONS: Although the metformin plus temozolomide regimen was well tolerated, it did not confer a clinical benefit in patients with recurrent or refractory GBM. Trial registration NCT03243851, registered August 4, 2017.PMID:37278858 | DOI:10.1007/s12672-023-00678-3
Source: Cancer Control - June 6, 2023 Category: Cancer & Oncology Authors: Wan-Soo Yoon Jong Hee Chang Jeong Hoon Kim Yu Jung Kim Tae-Young Jung Heon Yoo Se-Hyuk Kim Young-Cho Ko Do-Hyun Nam Tae Min Kim Se Hoon Kim Sung-Hae Park Youn Soo Lee Hyeon Woo Yim Yong-Kil Hong Seung Ho Yang Source Type: research
Multidisciplinary docking, kinetics and X-ray crystallography studies of baicalein acting as a glycogen phosphorylase inhibitor and determination of its' potential against glioblastoma in cellular models
Chem Biol Interact. 2023 Jun 3:110568. doi: 10.1016/j.cbi.2023.110568. Online ahead of print.ABSTRACTGlycogen phosphorylase (GP) is the rate-determining enzyme in the glycogenolysis pathway. Glioblastoma (GBM) is amongst the most aggressive cancers of the central nervous system. The role of GP and glycogen metabolism in the context of cancer cell metabolic reprogramming is recognised, so that GP inhibitors may have potential treatment benefits. Here, baicalein (5,6,7-trihydroxyflavone) is studied as a GP inhibitor, and for its effects on glycogenolysis and glioblastoma at the cellular level. The compound is revealed as a p...
Source: Chemico-Biological Interactions - June 5, 2023 Category: Molecular Biology Authors: Rachel T Mathomes Symeon M Koulas Ioannis Tsialtas George Stravodimos Philip J Welsby Anna-Maria G Psarra Izabela Stasik Demetres D Leonidas Joseph M Hayes Source Type: research
Yeast cell membrane-camouflaged PLGA nanoparticle platform for enhanced cancer therapy
J Control Release. 2023 Jun 3:S0168-3659(23)00356-5. doi: 10.1016/j.jconrel.2023.05.043. Online ahead of print.ABSTRACTTemozolomide (TMZ) is an oral DNA-alkylating drug used in colorectal cancer (CRC) chemotherapy. In this work, we proposed a safe and biomimetic platform for macrophages-targeted delivery of TMZ and O6-benzylguanine (O6-BG). TMZ was loaded in poly (D, l-lactide-coglycolide) (PLGA) nanoparticles, followed by sequential coating with O6-BG-grafted chitosan (BG-CS) layers and yeast shell walls (YSW) via layer-by-layer assembly (LBL) process, forming TMZ@P-BG/YSW biohybrids. Due to the yeast cell membrane-camouf...
Source: Cancer Control - June 5, 2023 Category: Cancer & Oncology Authors: Yu He Qi-Wen Chen Jin-Xin Yu Si-Yong Qin Wen-Long Liu Yi-Han Ma Xiao-Sui Chen Ai-Qing Zhang Xian-Zheng Zhang Yin-Jia Cheng Source Type: research
Lemur tyrosine kinase 2 has a tumor-inhibition function in human glioblastoma by regulating the RUNX3/Notch pathway
This study was carried out to determine the relevance of LMTK2 in GBM. Initiating investigation by assessing The Cancer Genome Atlas (TCGA) data showed LMTK2 mRNA levels were decreased in GBM tissue. Later examination of clinical specimens confirmed low levels of LMTK2 mRNA and protein in GBM tissue. The downregulated level of LMTK2 in patients with GBM was related to poor overall survival. A suppressive function of LMTK2 on the proliferative capability and metastatic potential of GBM cells was demonstrated by overexpressing LMTK2 in GBM cell lines. Moreover, the restoration of LMTK2 augmented the sensitivity of GBM cells ...
Source: Biochimica et Biophysica Acta - June 4, 2023 Category: Biochemistry Authors: Lei Zhang Peng Luo Xinggang Mao Jidong Sun Jialiang Wei Yuefan Yang Yanyu Zhang Xiaofan Jiang Source Type: research
